CONTACT.

Methods	Multi‐centre, double‐blind, randomized, placebo controlled trial
Participants	‐ aged 50 years or older ‐ diagnosis of probable Alzheimer's disease according to DSM‐IV‐TR and NINCDS‐ADRDA criteria ‐ MMSE between 5 and 14, inclusive ‐ stable on donepezil for 6 months prior to enrolment
Interventions	Participants were randomized to either: ‐ latrepirdine (10 mg PO TID for 1 week followed by 20 mg PO TID until endpoint) ‐ matched placebo Duration: 26 weeks Enrolment: ‐ 89 patients randomized
Outcomes	Primary ‐ NPI (behaviour) ‐ ADCS‐ADL severe (daily function)
Notes	Funding: Medivation Inc. and Pfizer Inc. ‐ this study was terminated on 7 May 2010 by the investigators due to lack of efficacy in the completed CONNECTION study. The authors maintain that termination was not due to safety concerns
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"randomized"
Allocation concealment (selection bias)	Unclear risk	This information has not been made available
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"double‐blind (subject, care‐giver, investigator)"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	"double‐blind (subject, care‐giver, investigator)"
Incomplete outcome data (attrition bias) All outcomes	High risk	This information has not been made available
Selective reporting (reporting bias)	High risk	Data on primary and secondary outcome measures have not been made available (ClinicalTrials.gov)
Other bias	Unclear risk	As the study has not been published by the study investigators and the information available in ClinicalTrials.gov is limited, we were not able to evaluate other sources of bias